|Videos|May 20, 2021

Dr. Ramasamy on 2-year follow-up data of oral testosterone capsule Jatenzo

Author(s)Urology Times staff

Ranjith Ramasamy, MD, explains how the oral testosterone capsule Jatenzo works and touches on key findings from a recent study of the treatment.

In this video, Ranjith Ramasamy, MD, discusses recent data regarding the oral testosterone capsule Jatenzo that were presented at ENDO 2021. Ramasamy is an associate professor of urology and director of male reproductive medicine and surgery at the University of Miami Miller School of Medicine.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Use of testosterone does not lead to abnormal hematocrit levels

ByHannah Clarke

November 27th 2023

Testosterone-Replacement therapy does not increase incidence of major adverse cardiac events for men with hypogonadism

ByCleveland Clinic

June 29th 2023

Study highlights how DTC online platforms often fail to convey risks of testosterone therapy

ByNorthwestern Medicine

December 8th 2022

Press Release

FDA approves oral testosterone replacement therapy for hypogonadism

ByUrology Times staff

August 4th 2022

Novel testosterone undecanoate capsule launched in US hypogonadism market

ByJason M. Broderick

June 9th 2022

Latest CME

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care

The Expert APProach: Advancing APP Leadership and Expertise in Urology, With Susanne Quallich, PhD, ANP-BC, NP-C

Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC

Precision Medicine and Patient Selection in mHSPC